HOME >> MEDICINE >> NEWS
Untangling prostaglandin signaling

Prostaglanin E2 (PGE2)signaling contributes to each of the manifestations that classically define inflammationredness, heat and pain. Although non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin are well kown to inhibit this pathway by blocking prostaglandin biosynthesis, more specific agents would be useful, given the disparate biological responses that prostaglanins mediate. Stock et al. now report the genetic disruption of the PGE2 receptor EP1, one of 4 such receptors, is responsible for pain perception and the regulation of blood pressure, 2 of the cardinal physiological responses to PGE2 signaling. The authors find that pained behavior by animals treated to provoke inflammation of the gut is decreased by half in the EP1-/- strain. Remarkably, NSAID treatment causes a similar 50% diminution of such responses in wild type mice and has little or no additional benefit in mutant animals, suggesting that most of the analgesic effect of these drugs can be explained by their inhibition of signaling through this single receptor type.

Stock and colleagues also observe a drop in systolic blood pressure in male mutants, which they attribute to impaired maintenance of the extracellular fluid volume. They also note that other aspects of blood pressure regulation have been found to occur differently in males and females, both in humans and in experimental animals. Thus, although pure EP1 antagonists might prove powerful and relatively specific analgesics, such drugs might also be expected to diminish blood pressure in men.


'"/>

Contact: John Ashkenas
scied@the-jci.org
416-946-7593
Journal of Clinical Investigation
30-Jan-2001


Page: 1

Related medicine news :

1. Understanding how prostaglandin prevents gut injury during radiation therapy
2. USC researchers find evidence that progesterone signaling influences ovarian cancer risk
3. Pancreatic cancer linked to developmental cell signaling pathway

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Untangling prostaglandin signaling

(Date:7/28/2015)... ... July 28, 2015 , ... BMI of Texas, which specializes in a variety ... weight loss surgery procedure. Committed to helping patients achieve their weight loss goals ... Texas is one of the first practices in South Texas to offer the ...
(Date:7/28/2015)... Nashville, Tenn. (PRWEB) , ... July 28, 2015 ... ... has added the SmileCareClub Invisible Aligner System to its online product ... , By using a teledentistry model and cloud-based technology, SmileCareClub allows patients to ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... ... 28, 2015 , ... The PULs Cardiac Test™ identifies asymptomatic ... many of whom are missed by conventional evaluation , A currently unmet ... sub-clinical disease, who are at risk of experiencing a coronary event, and for ...
(Date:7/28/2015)... ... July 28, 2015 , ... For ... Top Doctors, has based its selection process on the foundation of peer nominations. ... medical specialties, in any area of medicine and in any part of the ...
Breaking Medicine News(10 mins):Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 2Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 3Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3
(Date:7/28/2015)... -- According to a new market research report ... (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), ... published by MarketsandMarkets, the European Injectable Drug Delivery Market is ... in 2015, growing at a CAGR of 12.6% from 2015 ... market data T ables and 43 ...
(Date:7/27/2015)... July 28, 2015 CTI BioPharma Corp. (NASDAQ ... report its second quarter 2015 financial results on Thursday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Thursday, ...
(Date:7/27/2015)... DUBLIN and WESTLAKE VILLAGE, Calif. ... (NYSE: AGN ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: ... Trade Commission (FTC) has granted early termination of the ... 1976 (HSR Act) with respect to Allergan,s pending acquisition ... On July 6, 2015, each of ...
Breaking Medicine Technology:European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
Cached News: